Revisiting 5α-reductase inhibitors and the risk of prostate cancer

Cindy H. Chau, William D. Figg*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations


The role of 5α-reductase inhibitors (5-ARI) in prostate cancer chemoprevention remains a controversy, as cancer prevention trials with 5-ARIs have shown a decreased incidence of low-grade prostate cancer but a potential increased risk in high-grade disease. Recent studies have shed light on the long-term safety of 5-ARIs in terms of influencing prostate cancer risk.

Original languageEnglish
Pages (from-to)400-401
Number of pages2
JournalNature Reviews Urology
Issue number7
StatePublished - 1 Jul 2018
Externally publishedYes


Dive into the research topics of 'Revisiting 5α-reductase inhibitors and the risk of prostate cancer'. Together they form a unique fingerprint.

Cite this